


PD-L1-IN-5

Cat. No.:	HY-162357
CAS No.:	2597056-85-2
Molecular Formula:	C ₄₀ H ₄₄ ClFN ₄ O ₈
Molecular Weight:	763.25
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor, with the IC ₅₀ value of 785.6 nM. PD-L1-IN-5 has anti-tumor activity in vivo [1].																																			
In Vitro	PD-L1-IN-5 (X22) (0-150 μM, 12 h) has no obvious cytotoxic effect on MC38 and CT26 cells in vitro [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.																																			
In Vivo	<p>PD-L1-IN-5 (X22) (0-50 mg/kg/day for 20 days, p.o.) demonstrates significant antitumor efficacy in murine models of MC38 and CT26 colon cancer through the upregulation of tumor infiltration and cytotoxicity of CD8⁺ T cells partially, but exhibits low antitumor effect in the syngeneic CT26 colorectal cancer model in immunodeficient nude mice which indicated that the antitumor mechanism relies on the immune system [1].</p> <p>Pharmacokinetic Analysis in SD rats and C57blo/6 mice [1]</p> <table border="1"> <thead> <tr> <th>Animal model</th> <th>Route</th> <th>Dose (mg/kg)</th> <th>t_{1/2} (h)</th> <th>T_{max} (h)</th> <th>C_{max} (ng/mL)</th> <th>AUC_{0-t} (ng·h/mL)</th> <th>CL (mL/h/kg)</th> <th>F (%)</th> </tr> </thead> <tbody> <tr> <td>SD rat</td> <td>p.o.</td> <td>45</td> <td>4.3</td> <td>4.00</td> <td>49.8</td> <td>405.6</td> <td>/</td> <td>3.4</td> </tr> <tr> <td>C57blo/6 mice</td> <td>p.o.</td> <td>10</td> <td>1.6</td> <td>0.7</td> <td>255.7</td> <td>315.6</td> <td>/</td> <td>11.5</td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>MC38 and CT26 tumor mouse model, Balb/c mice (female, 8 week old) [1]</td> </tr> <tr> <td>Dosage:</td> <td>0-50 mg/kg/day for 20 days</td> </tr> <tr> <td>Administration:</td> <td>p.o.</td> </tr> <tr> <td>Result:</td> <td>Inhibited colon tumor growth in mice with tumor growth inhibition rates (TGI) of 49.5% and 73.6% at doses of 5 mg/kg and 25 mg/kg, respectively.</td> </tr> </table>	Animal model	Route	Dose (mg/kg)	t _{1/2} (h)	T _{max} (h)	C _{max} (ng/mL)	AUC _{0-t} (ng·h/mL)	CL (mL/h/kg)	F (%)	SD rat	p.o.	45	4.3	4.00	49.8	405.6	/	3.4	C57blo/6 mice	p.o.	10	1.6	0.7	255.7	315.6	/	11.5	Animal Model:	MC38 and CT26 tumor mouse model, Balb/c mice (female, 8 week old) [1]	Dosage:	0-50 mg/kg/day for 20 days	Administration:	p.o.	Result:	Inhibited colon tumor growth in mice with tumor growth inhibition rates (TGI) of 49.5% and 73.6% at doses of 5 mg/kg and 25 mg/kg, respectively.
Animal model	Route	Dose (mg/kg)	t _{1/2} (h)	T _{max} (h)	C _{max} (ng/mL)	AUC _{0-t} (ng·h/mL)	CL (mL/h/kg)	F (%)																												
SD rat	p.o.	45	4.3	4.00	49.8	405.6	/	3.4																												
C57blo/6 mice	p.o.	10	1.6	0.7	255.7	315.6	/	11.5																												
Animal Model:	MC38 and CT26 tumor mouse model, Balb/c mice (female, 8 week old) [1]																																			
Dosage:	0-50 mg/kg/day for 20 days																																			
Administration:	p.o.																																			
Result:	Inhibited colon tumor growth in mice with tumor growth inhibition rates (TGI) of 49.5% and 73.6% at doses of 5 mg/kg and 25 mg/kg, respectively.																																			

REFERENCES

[1]. Liu L, et al. Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity. J Med Chem. 2024 Mar 28;67(6):4977-4997.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA